GlassScriptPhysician profile
Vandana Pai
NPI 1699156620
$10,036.84
in general payments reported to CMS, 2019-2025
34 companies · $2,732 in 2025
The $2,732 reported for 2025 was more than what 81% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $194 · 2022: $2,462 · 2023: $2,184 · 2024: $2,465 · 2025: $2,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,256 · Education: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,255.99 |
| Education | $124.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,146.71 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,313.22 | 2022-2025 | Tezspire, Airsupra, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $971.01 | 2021-2025 | Ofev, Stiolto Respimat, Spiriva Respimat |
| Actelion Pharmaceuticals US, INC. | $930.70 | 2021-2025 | Uptravi, Opsumit |
| Electromed, INC. | $634.61 | 2022-2025 | Smartvest |
| Grifols USA, LLC | $527.84 | 2021-2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $458.91 | 2021-2025 | Glassia, Cuvitru |
| Regeneron Healthcare Solutions, INC. | $425.91 | 2021-2025 | Dupixent |
| Genzyme Corporation | $415.27 | 2022-2025 | |
| Mylan Specialty L.P. | $386.52 | 2021-2024 | Yupelri |
| Amgen INC. | $230.27 | 2022-2025 | Tezspire |
| Merck Sharp & Dohme LLC | $163.74 | 2023-2025 | Winrevair, Zerbaxa, Recarbrio |
| Insmed, INC. | $149.64 | 2025 | Arikayce, Brinsupri |
| Viatris Specialty LLC | $149.09 | 2025 | Yupelri |
| Inogen, INC. | $143.94 | 2022-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $143.49 | 2022-2025 | Acthar |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $80.89 | 2022-2024 | |
| Covis Pharma Gmbh | $76.70 | 2022 | |
| Philips North America LLC | $73.44 | 2021-2023 | |
| Verona Pharma, INC. | $67.73 | 2025 | Ohtuvayre |
| Idorsia Pharmaceuticals US INC | $61.68 | 2024 | Quviviq |
| Pfizer INC. | $57.79 | 2022-2023 | |
| Baxter Healthcare | $56.73 | 2023 | Hillrom - Life 2000 Ventilation System |
| Csl Behring | $54.25 | 2024 | Kcentra |
| Axsome Therapeutics, INC. | $39.50 | 2023-2024 | Sunosi |
| Abbvie INC. | $39.16 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $26.37 | 2022 | |
| United Therapeutics Corporation | $24.45 | 2022 | |
| Paratek Pharmaceuticals, INC. | $22.09 | 2022 | |
| Pulmonx Corporation | $18.93 | 2024 | Pulmonx Chartis Tablet Console, Zephyr Delivery Catheter, Zephyr Endobronchial Valve |
| Genentech USA, INC. | $17.69 | 2022 | |
| Optinose US, INC. | $15.29 | 2024 | |
| Nabriva Therapeutics, Plc | $14.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vandana Pai listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.